MANILA, Philippines — Vaccine czar Carlito Galvez Jr. on Wednesday emphasized the need for an indemnity law governing the procurement of coronavirus vaccines from the COVAX pool,citing the misgivings of vaccine manufacturers arising from the Dengvaxia controversy.
In 2017, the Department of Health (DOH) suspended a massive dengue immunization program after French pharmaceutical giant, Sanofi Pasteur, belatedly announced that its vaccine, Dengvaxia, could lead to more severe symptoms for people who had not previously been infected.
“‘Yun [indemnity agreement] ang hinihingi ng ating mga manufacturer kasi nakita natin na napakalaki ng takot ng mga manufacturer sa Dengvaxia na nakita…
Keep on reading: Dengvaxia controversy casts shadow over COVID-19 vaccine procurement